Bio-Techne shareholders approve Merck KGaA acquisition, deal expected to close by early 2027

Bio-Techne shareholders have voted to approve the acquisition agreement with Merck KGaA, marking a key step toward completing the merger. The deal, which combines Bio-Techne's life science tools with Merck's global capabilities, aims to enhance support across research and manufacturing workflows. The transaction is expected to close by late 2026 or early 2027, pending regulatory approvals and customary closing conditions. This merger will provide immediate cash value to Bio-Techne shareholders and position the combined company as a leader in life sciences.

Following the shareholder approval for Merck KGaA's acquisition of Bio-Techne, the stock remains stable on Pluang as of Sep 23, 2026 20:31 WIB, trading at USD 72.53 with a minimal 1-day change of -0.03%. Bio-Techne's market cap stands at $11.38 billion, close to its 52-week high of $72.55, reflecting steady investor interest during this transition period.